Why Glycomark

Why GlycoMark?

In 2011, more than 25.8 million people in the U.S. had diabetes (8.3% of the population). Nearly 2 million are diagnosed with diabetes each year. Another 7 million are undiagnosed and 79 million (25% of the population) have pre-diabetes. Complications from diabetes are numerous and costly, including cardiovascular disease and stroke, blindness, kidney disease and amputations.

More information. Better control.

The GlycoMark test is an indicator of hyperglycemia and glycemic variability. Hyperglycemia and glycemic variability have been linked to diabetes-related health complications including:

  • vascular damage (reduced flow-mediated dilation and coronary lumen diameter; increased carotid artery stiffness and carotid intima-media thickness)
  • oxidative stress (plasma 3-nitrotyrosine and 24-h urinary excretion rates of free 8-iso PGF2)
  • increased inflammatory markers (C-Reactive Protein, Interleukin 6)
  • poor cardiovascular outcomes (repeat MI, acute heart failure)
  • stroke
  • dementia
  • increased risk of death from cardiovascular causes

By measuring 1,5-anhydroglucitol in the blood and yielding a precise one- to two-week profile of average daily maximum blood glucose, GlycoMark can help you:

  • identify patients with A1Cs at 8% or less who have had more frequent and extreme hyperglycemic excursions in the past one to two weeks
  • recognize recent glycemic deterioration before changes are visible with A1C
  • record improvements in therapy changes within two to four weeks
  • measure and positively reinforce adherence to dietary and lifestyle changes

With more information, you can do more to establish and maintain target blood glucose levels.


GlycoMark reveals what other tests can’t.

The GlycoMark test can be used in addition to traditional blood glucose tests, like hemoglobin A1C or fasting blood sugar, but offers information that other tests do not reveal.

  • Hemoglobin A1C (also known as HbA1C or A1C) is a measure of average blood glucose over the previous 2-3 months. However, patients can be experiencing many hyperglycemic excursions that are balanced out by low glucose levels. On average, blood glucose may appear to be well controlled.
  • Fructosamine (FA) and Glycated Albumin (GA) are two shorter-term (two- to four-week) markers, but like A1C, also reflect an average of blood glucose levels.
  • Fasting Blood Glucose (FBG) reflects fasting blood sugar at the time the test is done.
  • Self-monitoring of blood glucose (SMBG) reflects current blood glucose at the time of the test, but can miss peak blood glucoses because of timing.

The GlycoMark test reflects average maximum blood glucose over the past two weeks, including changes that can occur in just a few days if peak blood glucose goes up or down. Because it can be ordered more often, GlycoMark gives a more current and complete profile of glycemic health than other testing methods alone.

Adding GlycoMark provides greater accuracy than A1C alone

The GlycoMark and A1C tests are both measures of intermediate blood glucose control. But they differ significantly in the data they present.

In as many as 15% of patients, A1C scores are inaccurate due to red blood cell anomalies. And, as an average measure, A1C is inherently incomplete*. Nearly 40% of patients whose A1C scores indicate good control of diabetes may suffer significant glucose fluctuations that don’t show up in an A1C average**.

By contrast, 1,5 AG has been shown to identify specific hyperglycemic peaks, providing detailed, accurate information that can be masked by an average value.

*Hirsch et al Diab Technol Ther 2012; **Bonora et al Diabetologia 2006.

Information patients can use.

The more your patients know about hyperglycemia management, the more receptive they may be to changes in therapy and behavior. And the more likely they will be to adhere to their therapeutic regimen.

Well-informed patients are prepared and motivated to participate more fully in their treatment. With GlycoMark, patients get a quicker measure of improvements and progress toward compliance than they get with A1C. GlycoMark can give feedback in just two to four weeks instead of the three-month wait for a new A1C score. GlycoMark helps them hit—and hold—their mark.

A new, more personal dimension in glycemic surveillance.

The GlycoMark test provides a new dimension in glycemic surveillance. Using the current data only GlycoMark provides, you can adjust treatment strategies to not only reach and maintain target A1C’s, but find the balance in controlling glucose spikes. The GlycoMark test tells you what you need to know in order to personalize your patient’s hyperglycemia management.

Note: The following information concerning hypothetical patients is not medical advice, and physicians should use their best clinical judgment in the use of the GlycoMark test in the treatment of the patient. The suggested Personalized Therapy Algorithm is adapted from Dungan, Expert Rev Mol Diagn 8(1), 2008; Drug choices for prandial vs. fasting/baseline control adapted from AACE and IDF treatment guidelines for Type 2 diabetes.

Two patients. Identical A1Cs. The rest of the picture.

You have two patients, Mary and William. Both have A1Cs of 7.4%, but Mary has higher glucose peaks while William has high glucose levels overall. Both indicate they feel well, but admit that they have not been checking their fingerstick glucoses routinely.

Because you also ordered the GlycoMark test, you know that Mary has a GlycoMark result of 3.4 while William’s GlycoMark result is 15.1. With that knowledge, you can devise personalized treatment plans for your patients.

Note the time Mary spent above the ADA’s recommended postprandial goal of 180 mg/dL. Mary experienced frequent extreme glucose peaks.

Things to consider for Mary’s Treatment Plan:

  • Ask Mary if anything unusual has happened in the past few weeks that might cause high blood glucose (illness, ran out of medication, cortisone injection, vacation, etc.).
  • Ensure Mary has no advanced (Stage 4 or 5) kidney or liver disease.
  • Have Mary self-test pre/postmeal blood sugars for several days to identify a pattern or use a continuous glucose monitor (CGM).
  • If postmeal blood sugars are high, consider appropriate prandial medication.
  • Consider diet counseling.
  • Draw a GlycoMark test again within 30 days to check the effectiveness of treatment plan.

Note the time William spent above the ADA’s recommended postprandial goal of 180 mg/dL.  William had a high baseline glucose overall.

Things to consider for William’s Treatment Plan:

  • William’s peak blood sugars appear to be well controlled.
  • Consider increasing or adding medication to address baseline glucose control to get closer to target A1C < 7%.
  • Consider modifying William’s diet and exercise plan.
  • Draw an “A1C with reflex to GlycoMark” in 60-90 days to check if A1C < 7% and GlycoMark value remains high.

Information is advantage. Order the GlycoMark test

The GlycoMark test has been clinically proven in more than 40 studies worldwide involving people with type 1, type 2 and gestational diabetes, pediatrics and people with kidney disease. It has been shown to correlate with other measures of glucose control, including continuous glucose monitors, oral glucose tolerance tests, A1C and fructosamine.

When you order blood glucose tests, include GlycoMark. It fills information gaps left by others, completing the picture of glycemic control. In the treatment and management of hyperglycemia, enhanced information is a critical advantage. That’s why GlycoMark should be part of your basic testing regimen. The GlycoMark test is available through most commercial laboratories.

What Doctors Say

Testimonials WATCH HERE

Clinical guide

Find a Lab

Read our newsletter